EDA2R and plasma cell myeloma: In particular, compared with healthy controls, patients with various diseases, including acute myeloid leukaemia, alcohol‐related liver disease, chronic liver disease, E. coli pyelonephritis, hepatocellular carcinoma, metabolic dysfunction‐associated steatotic liver disease, metastatic melanoma, myeloma, myositis, pancreatic cancer, paediatric kidney tumour, pneumococcal pneumonia, Staphylococcus aureus bacteremia, streptococcal soft tissue infection, systemic lupus erythematosus, systemic sclerosis and viral hepatitis–related cirrhosis, showed significantly higher plasma levels of EDA2R.